E

    Exicure Inc (XCUR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.31
    +0.02 (+1.55%)

    Market Cap: $8.44M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    42%(8/19)
    Avg Surprise
    +113.75%
    Streak
    1 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.18N/AN/ABeat+84.9%
    Sep 25
    		$-0.39$0.00N/AMiss+32.1%
    Jun 25
    		$-0.41N/AN/ABeat-490.8%
    Mar 25
    		$0.49N/AN/ABeat+180.1%
    Dec 24
    		$-1.19N/AN/ABeat-593.1%
    Sep 24
    		$-0.57N/AN/ABeat+5.5%
    Jun 24
    		$-0.07N/AN/ABeat+90.1%
    Mar 24
    		$-0.61$0.00N/AMiss-114.8%
    Dec 23
    		$-0.17N/AN/ABeat+83.5%
    Sep 23
    		$-0.61$0.00N/AMiss+92.7%
    Jun 23
    		$-0.70N/AN/ABeat+93.3%
    Dec 22
    		$4.10$-0.19+2257.89%Beat+191.1%
    Sep 22
    		$-1.04$-0.90-15.56%Miss+97.4%
    Jun 22
    		$-8.30$-6.00-38.33%Miss+65.4%
    Mar 22
    		$-10.50$-10.50+0.00%Beat+50.0%
    Dec 21
    		$-4.50$-4.20-7.14%Miss-7.1%
    Sep 21
    		$-40.50$-22.50-80.00%Miss-170.0%
    Jun 21
    		$-24.00$-19.50-23.08%Miss-220.0%
    Mar 21
    		$-21.00$-16.50-27.27%Miss-1500.0%
    Dec 20
    		$-4.20$-3.12-34.62%Miss-7.7%
    Sep 20
    		$-15.00$-13.88-8.07%Miss-11.1%
    Jun 20
    		$-7.50$-12.75+41.18%Beat+58.3%
    Mar 20
    		$1.50N/A+111.11%Beat+108.3%
    Dec 19
    		$-3.90$-2.62-48.85%Miss-30.0%
    Sep 19
    		$-13.50$-12.00-12.50%Miss+30.8%
    Jun 19
    		$-18.00$-19.50+7.69%Beat+29.4%
    Mar 19
    		$-18.00$-18.00+0.00%Beat-12757.1%
    Dec 18
    		$-3.00$-4.50+33.33%Beat-
    Sep 18
    		$-19.50$-24.00+18.75%Beat-
    Jun 18
    		$-25.50$-22.50-13.33%Miss-
    Mar 18
    		$-0.14N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-2.66EV/EBITDA-0.04x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-168.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio0.56xQuick Ratio0.56x
    Trading Statistics
    Beta3.66Avg Volume45.56K
    52-Week High$9.4852-Week Low$1.05

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.29
    SMA 20$1.33
    SMA 50$1.69
    SMA 200$3.60
    EMA 10$1.30
    EMA 20$1.38
    EMA 50$1.73
    EMA 200$3.39

    MACD

    Line: -0.12Signal: -0.15Hist: 0.03

    ADX

    ADX: 28.4+DI: 18.4-DI: 23.9

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down76.0
    PSAR$1.07

    Bollinger Bands

    Upper Band$1.55
    Lower Band$1.12
    %B Position3198%(Upper)
    Band Width0.44

    RSI (14-Day)

    Neutral
    43.0

    Momentum Oscillators

    Stoch %K65.2
    Stoch %D60.1
    Williams %R-40.9
    ROC (10d)-5.1%
    Momentum-0.07
    CCI (20d)-19.9
    MFI (14d)44.4

    Volatility Measures

    ATR (14d)$0.16(12.0%)
    StdDev (20d)0.11
    Hist Vol104.3%(High)

    Volume Flow

    VWAP$1.31
    OBV37.0M
    AD Line-33.5M
    CMF (20d)-0.043

    Volume Metrics

    Avg Vol (20d)45.2K
    Vol Ratio0.5x(Low)
    VWMA (20d)$1.33

    Pivot Points

    R3$1.47
    R2$1.44
    R1$1.36
    Pivot Point$1.33
    S1$1.25
    S2$1.22
    S3$1.14

    Advanced Oscillators

    TSI-23.53
    Ultimate Osc48.0
    KST-222.55

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$500,000$0$0
    Cost of Revenue$0$0$157,000$0$0$0$404,000$0$0$0N/A$0
    Gross Profit$0$0$-157,000$0$0$0$-96,000$0$0$500,000N/A$0
    Operating Expenses$1.05M$1.64M$2.28M$2.39M$2.51M$-2,923,000$7.59M$2.57M$1.24M$1.34M$1.50M$3.32M
    R&D$174,000$312,000$655,000$888,000$935,000$808,000$0$0$0$0$0$0
    SG&A$889,000$1.29M$1.60M$1.50M$1.51M$2.22M$1.44M$1.43M$1.24M$1.34M$560,000$2.40M
    Operating Income$-1,054,000$-1,640,000$-2,282,000$-2,391,000$-2,509,000$2.92M$-7,589,000$-2,572,000$-1,235,000$-836,000$-1,498,000$-3,317,000
    Interest Income$11,000$0$-8,000$56,000$56,000$32,000$1,000$1,000$4,000$7,000$11,000$17,000
    Interest Expense$67,000$188,000$1.25M$0$112,000$0$0$12,000$0$0$0$0
    Income Before Tax$-1,121,000$-1,828,000$-3,532,000$-2,437,000$-2,621,000$3.01M$-7,181,000$-1,083,000$-600,000$-829,000$-1,487,000$-5,256,000
    Income Tax Expense$0$0$-634,000$0$0$0$0$8,000$0$0$0$0
    Net Income$-1,121,000$-1,828,000$-2,898,000$-2,437,000$-2,621,000$3.01M$-7,181,000$-1,091,000$-600,000$-829,000$-1,487,000$-5,256,000
    EBITDA$-1,092,000$-1,722,000$-3,366,000$-2,426,000$-2,549,000$3.09M$-6,964,000$-864,000$-401,000$-635,000$-1,301,000$-4,938,000
    EBIT$-1,132,000$-1,828,000$-3,523,000$-2,493,000$-2,677,000$2.98M$-7,176,000$-1,072,000$-604,000$-836,000$-1,498,000$-5,273,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about XCUR

    News

    EXICURE, INC. Q2 2026: Revenue $0 Net income $(1.12M) — 10-Q Summary

    EXICURE, INC. reported Q2 2026 results with no revenue and a net loss of $(1.12M), an improvement year-over-year. The company has shifted its strategic focus to supporting clinical programs for GPCR USA post-acquisition, implementing operational cutbacks, and addressing Nasdaq compliance issues. Financial highlights include a widening six-month loss despite the quarterly improvement.

    TradingView•8/14/26•
    Somewhat-Bearish

    Exicure Deadline Alert

    Faruqi & Faruqi, LLP is investigating potential claims against Exicure, Inc. (NASDAQ: XCUR) and reminds investors of the February 11, 2022 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Exicure made false and misleading statements regarding improprieties in its preclinical program for Friedreich's ataxia, leading to a significant drop in its stock price. Investors who suffered losses exceeding $100,000 between March 11, 2021 and November 15, 2021 are encouraged to contact the firm.

    TMX Newsfile•8/12/26•
    Bearish

    Exicure Inc (XCUR) Earnings Forecast: Future EPS & Revenue Growth Estimates

    This article provides an earnings forecast for Exicure Inc (XCUR), focusing on future EPS and revenue growth estimates. It includes current stock information such as share price, market cap, and daily performance. The page also features a peer comparison table with ratings and analyst coverage for other biotechnology companies.

    TradingKey•8/10/26•
    Neutral

    Exicure Inc (XCUR) Stock News Today

    This page provides an overview of Exicure Inc (XCUR) stock, including its current price, market cap, and a note that more news is coming soon. The stock closed at $1.345, down 0.74% on August 7th. It also lists various financial and analytical tools available on the TradingKey platform for XCUR.

    TradingKey•8/8/26•
    Neutral

    Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

    Exicure, Inc. announced its intention to settle a $1.0 million clinical milestone payment to GPCR Therapeutics, Inc. by issuing 172,058 shares of its common stock in August 2026. This payment was triggered by the completion of the Phase 2 clinical trial for Burixafor (GPC-100). The company stated this equity issuance will help preserve cash and maintain financial flexibility.

    Yahoo Finance Singapore•8/4/26•
    Somewhat-Bullish

    Frequently Asked Questions About XCUR

    Does XCUR pay dividends?
    Exicure Inc (XCUR) does not currently pay a regular dividend.
    What is XCUR's market cap?
    Exicure Inc (XCUR) has a market capitalization of $8.44M with a current stock price of $1.31.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In